


# Interim Clinical Considerations Update: Moderna COVID-19 Vaccine for Children Ages 6–17

Elisha Hall, PhD

Clinical Guidelines Lead



Advisory Committee on Immunization Practices Meeting  
6/24/2022



[cdc.gov/coronavirus](https://cdc.gov/coronavirus)

# COVID-19 Pediatric Vaccination Schedule




# Pediatric Schedule: Moderna COVID-19 Vaccine

People who are **NOT** moderately or severely immunocompromised

Moderna  
(6 years-  
17 years)


## Primary Series



People who **ARE** moderately or severely immunocompromised


Moderna  
(6 years-  
17 years)

## Primary Series




# Pediatric Schedule: People Who Are NOT Moderately or Severely Immunocompromised


**Moderna**  
(6 months–  
17 years)



**Pfizer-BioNTech**  
(6 months–  
4 years)




**Pfizer-BioNTech**  
(5 years–  
17 years)




# Pediatric Schedule: People Who ARE Moderately or Severely Immunocompromised


**Moderna**  
(6 months–  
17 years)




**Pfizer-BioNTech**  
(6 months–  
4 years)




**Pfizer-BioNTech**  
(5 years–  
11 years)



**Pfizer-BioNTech**  
(12 years–  
17 years)



# Considerations for Extended Interval Between Dose 1 & 2



- Immunocompromised
- High risk for severe disease
- Household members with high risk for severe disease
- High COVID-19 community levels

- Reduced myocarditis risk
- Adolescent and young adult males
- Optimize vaccine effectiveness

# Products



# Moderna COVID-19 Vaccine Products

Authorized Age group	 <b>6 months–5 years</b> (primary series)	 <ul style="list-style-type: none"> <li>• <b>6–11 years</b> (primary series)</li> <li>• <b>18 years and older</b> (booster doses)</li> </ul>	 <ul style="list-style-type: none"> <li>• <b>12 years and older</b> (primary series)</li> <li>• <b>18 years and older</b> (booster doses)</li> </ul>
Vial cap color	Dark blue	Dark blue	Red
Label border color	Magenta	Purple	Light blue
Dose (mRNA concentration)	25 mcg	50 mcg	100 mcg
Injection volume volume	0.25 mL	0.5 mL	0.5 mL(primary, age 12+); 0.25mL(booster, age 18+)
Dilution required	No	No	No
Doses per vial	10	5	Maximum of 11




# Moderna COVID-19 Vaccine Products

Authorized Age group	 <b>6 months–5 years</b> (primary series)	 <ul style="list-style-type: none"> <li>• 6–11 years (primary series)</li> <li>• 18 years and older (booster doses)</li> </ul>	 <ul style="list-style-type: none"> <li>• 12 years and older (primary series)</li> <li>• 18 years and older (booster doses)</li> </ul>
Vial cap color	Dark blue	Dark blue	Red
Label border color	Magenta	Purple	Light blue
Dose (mRNA concentration)	25 mcg	50 mcg	100 mcg
Injection volume	0.25 mL	0.5 mL	0.5 mL (primary, age 12+); 0.25 mL (booster, age 18+)
Dilution required	No	No	No
Doses per vial	10	5	Maximum of 11

# Moderna COVID-19 Vaccine Products

Authorized Age group	 6 months–5 years (primary series)	 <ul style="list-style-type: none"> <li>• 6–11 years (primary series)</li> <li>• 18 years and older (booster doses)</li> </ul>	 <ul style="list-style-type: none"> <li>• 12 years and older (primary series)</li> <li>• 18 years and older (booster doses)</li> </ul>
Vial cap color	Dark blue	Dark blue	Red
Label border color	Magenta	Purple	Light blue
Dose (mRNA concentration)	25 mcg	50 mcg	100 mcg
Injection volume volume	0.25 mL	0.5 mL	0.5 mL(primary, age 12+); 0.25mL(booster, age 18+)
Dilution required	No	No	No
Doses per vial	10	5	Maximum of 11

# Moderna COVID-19 Vaccine Product for Ages 6–11 Years



Labeled for “BOOSTER  
DOSES ONLY” but is  
authorized for:

- Primary doses in  
children ages 6–11  
years
- Booster doses in  
adults ages 18  
years and older

# Moderna COVID-19 Vaccine Products

Authorized Age group	 6 months–5 years (primary series)	 <ul style="list-style-type: none"> <li>• 6–11 years (primary series)</li> <li>• 18 years and older (booster doses)</li> </ul>	 <ul style="list-style-type: none"> <li>• 12 years and older (primary series)</li> <li>• 18 years and older (booster doses)</li> </ul>
Vial cap color	Dark blue	Dark blue	Red
Label border color	Magenta	Purple	Light blue
Dose (mRNA concentration)	25 mcg	50 mcg	100 mcg
Injection volume	0.25 mL	0.5 mL	0.5 mL(primary, age 12+); 0.25mL(booster, age 18+)
Dilution required	No	No	No
Doses per vial	10	5	Maximum of 11

# FDA Resources

## Wall chart:

<https://www.fda.gov/media/159306/download>

MODERNA COVID-19 VACCINE PRESENTATIONS				
Age Group	6 months through 5 years (Primary Series)	6 years through 11 years (Primary Series)  Currently unavailable (Use the vial with dark blue cap and a label with a purple border)	6 years through 11 years (Primary Series)  18 years and older (Booster Dose)	12 years and older (Primary Series)  18 years and older (Booster Dose)
Vial Cap Color	Dark Blue	Dark Blue	Dark Blue	Red
Vial Label Border Color	MAGENTA	TEAL	PURPLE	LIGHT BLUE
Vial Image				
Primary Dose Volume	0.25 mL	0.5 mL	0.5 mL	0.5 mL
Booster Dose Volume	None	None	0.5 mL	0.25 mL
For storage and expiry information, see FDA-authorized Fact Sheet or scan QR code.	 <a href="https://www.modernatx.com/covid19vaccine-eua">www.modernatx.com/covid19vaccine-eua</a>	 <a href="https://www.modernatx.com/covid19vaccine-eua">www.modernatx.com/covid19vaccine-eua</a>	 <a href="https://www.modernatx.com/covid19vaccine-eua">www.modernatx.com/covid19vaccine-eua</a>	 <a href="https://www.modernatx.com/covid19vaccine-eua">www.modernatx.com/covid19vaccine-eua</a>

## FACT SHEET FOR HEALTHCARE PROVIDERS ADMINISTERING VACCINE (VACCINATION PROVIDERS) EMERGENCY USE AUTHORIZATION (EUA) OF THE MODERNA COVID-19 VACCINE TO PREVENT CORONAVIRUS DISEASE 2019 (COVID-19)

### PRIMARY SERIES 6 years through 11 years of age

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product, Moderna COVID-19 Vaccine, for active immunization to prevent COVID-19 in individuals 6 months of age and older.

There are 2 presentations of Moderna COVID-19 Vaccine authorized for use to provide primary series doses to individuals 6 years through 11 years of age:

- The presentation supplied in a multiple-dose vial with a dark blue cap and a label with a purple border (see image below). The cartons and vial labels state "BOOSTER DOSES ONLY." This presentation may be used to provide primary series doses to individuals 6 years through 11 years of age. The Moderna COVID-19 Vaccine is not authorized to provide booster doses to individuals 6 years through 11 years of age.<sup>1</sup>



<sup>1</sup> The multiple-dose vials with dark blue caps and labels with a purple border are authorized to provide 0.5 mL primary series doses to individuals 6 years through 11 years of age and to provide 0.5 mL booster doses to individuals 18 years of age and older.

Revised: June/17/2022

## FOR HEALTHCARE PROVIDERS ADMINISTERING VACCINE (VACCINATION PROVIDERS) EMERGENCY USE AUTHORIZATION (EUA) OF THE MODERNA COVID-19 VACCINE TO PREVENT CORONAVIRUS DISEASE 2019 (COVID-19)

### PRIMARY SERIES AND BOOSTER DOSE PRESENTATION Primary Series Doses for 12 Years and Older Booster Doses for 18 Years and Older<sup>1</sup>

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product, Moderna COVID-19 Vaccine, for active immunization to prevent COVID-19 in individuals 6 months of age and older.

There are 2 presentations of Moderna COVID-19 Vaccine authorized for use to provide primary series doses to individuals 12 years of age and older:

- The presentation supplied in a multiple-dose vial with a dark blue cap and a label with a light blue border which is authorized for use to provide primary series doses to individuals 12 years of age and older; and
- The presentation supplied in a multiple-dose vial with a red cap and a label with a light blue border which is authorized for use to provide booster doses to individuals 18 years of age and older who have completed a primary series with Moderna COVID-19 Vaccine or SPIKEVAX (COVID-19 Vaccine, mRNA) (Moderna, Inc.).

The presentation supplied in a multiple-dose vial with a dark blue cap and a label with a light blue border is authorized for use to provide primary series doses to individuals 12 years of age and older who have completed a primary series with another authorized or approved COVID-19 vaccine. The presentation supplied in a multiple-dose vial with a red cap and a label with a light blue border is authorized for use to provide booster doses to individuals 18 years of age and older who have received a primary series dose of any authorized or approved COVID-19 vaccine; and

The presentation supplied in a multiple-dose vial with a red cap and a label with a light blue border is authorized for use to provide booster doses to individuals 18 years of age and older who have received a primary series dose of any authorized or approved COVID-19 vaccine; and

The presentation supplied in a multiple-dose vial with a red cap and a label with a light blue border is authorized for use to provide booster doses to individuals 18 years of age and older who have received a primary series dose of any authorized or approved COVID-19 vaccine; and

## Fact Sheet for Healthcare Providers

- 6 Through 11 Years:

<https://www.fda.gov/media/159308/download>

- 12 Years and Older:

<https://www.fda.gov/media/157233/download>

# CDC Resources

- Clinical considerations:  
<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html>
- Self-paced training module:  
<https://www2.cdc.gov/vaccines/ed/covid19/moderna/index.asp>
- Job aids: <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/index.html>
  - At-a-glance job aid for each manufacturer
  - Prep and admin summary
- Promotion through webinars, calls, and partners

**Moderna COVID-19 Vaccine At-A-Glance**  
Blue cap: 6 Months through 5 Years of Age  
Red cap: 18 years of age and older

**Preparation and Administration Basics**  
**NOTE:** Find additional guidance on properly preparing and administering the vaccine at:  

- CDC's COVID-19 Clinical materials for Moderna COVID-19 Vaccine: [www.cdc.gov/vaccines/covid-19/info-by-product/moderna/index.html](https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/index.html)
- CDC's Vaccine administration library: [www.cdc.gov/vaccines/hcp/admin/resource-library.html](https://www.cdc.gov/vaccines/hcp/admin/resource-library.html)

**Preparation and Administration**

**Moderna COVID-19 Vaccine At-A-Glance**  
Blue cap: 6 Months through 5 Years of Age  
Red cap: 18 years of age and older

The tables below summarize basic storage, preparation, scheduling, administration, and dosage for Moderna COVID-19 Vaccine.

**EUA Fact Sheet**  
[www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/spikevax-and-moderna-covid-19-vaccine](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/spikevax-and-moderna-covid-19-vaccine)

**CDC Interim Clinical Considerations**  
[www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html)

**CDC Clinical Materials**  
[www.cdc.gov/vaccines/covid-19/info-by-product/moderna](https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna)

**Interim COVID-19 Vaccination Schedule**  
[www.cdc.gov/vaccines/covid-19/download/covid-19-immunization-schedule-ages-5yrs-older.pdf](https://www.cdc.gov/vaccines/covid-19/download/covid-19-immunization-schedule-ages-5yrs-older.pdf)

**Storage and Handling Basics**  
**NOTE:** Find additional guidance on storing the vaccine properly at:  

- CDC's COVID-19 Clinical materials for Moderna COVID-19 Vaccine: [www.cdc.gov/vaccines/covid-19/info-by-product/moderna/storage](https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/storage)
- CDC's Storage and Handling Toolkit: [www.cdc.gov/vaccines/hcp/admin/storage/toolkit/storage-handling-toolkit.pdf](https://www.cdc.gov/vaccines/hcp/admin/storage/toolkit/storage-handling-toolkit.pdf)

Vial cap color	Blue cap with magenta bordered label	Red cap with blue bordered label
<b>Ages</b>	<b>6 months through 5 years</b>	<b>18 years and older</b>
<b>Supplied in multidose vial</b>	10 primary doses (0.25 mL) per vial	<b>Per vial:</b> <ul style="list-style-type: none"> <li>• 10 primary doses (0.5 mL) or</li> <li>• 20 booster doses (0.25 mL)</li> </ul> Discard vial and any remaining vaccine after 20 punctures.
<b>Storage Temperature: Before Puncture</b>	<b>Between:</b> -50°C and -15°C (-58°F and 5°F) until the expiration date 2°C and 8°C (36°F and 46°F) for up to 30 days 8°C and 25°C (46°F and 77°F) for a total of 24 hours. Discard vial and unused vaccine after 24 hours.	
<b>Thawing Frozen Vaccine</b> <b>Do NOT refreeze thawed vaccine.</b>	<b>Between:</b> 2°C and 8°C (36°F and 46°F) for 2 hours. Let each vial stand at room temperature for 15 minutes before administering. OR 15°C and 25°C (46°F and 77°F) for 45 minutes.	
<b>Storage Temperature: After Puncture</b>	<b>Between:</b> 2°C and 25°C (36°F and 77°F) for up to 12 hours. Discard vial and any unused vaccine after 12 hours.	


9 vaccine based on age and immune status. For <https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/>

# Vaccine Dosage

- Children should receive the age-appropriate vaccine product and follow the schedule based on their age **on the day of vaccination**, regardless of their size or weight.
- If a child moves from a younger age group to an older age group (e.g., moves from age 11 years to age 12 years) during the primary series or between the primary series and receipt of the booster dose(s), they should receive the vaccine dosage for the older age group for all subsequent doses.

# Children who Turn from Age 5 to 6 Years Between Any Dose in the Primary Series May Receive...


...for either dose: 1) The Moderna product authorized for children ages 6 months–5 years or 2) the Moderna product authorized for children ages 6–11 years.





# Children who Turn from Age 11 to 12 Years Between Any Dose in the Primary Series May Receive...

...for either dose: 1) the Moderna product authorized for children ages 6–11 years, 2) The Moderna product authorized for children ages 12–17 years.



# Vaccine Administration



# Administration

- Existing guidance applies to children and adolescents ages 6–17 years.
- Coadministration: COVID-19 vaccines may be administered without regard to timing of other vaccines.
  - Considerations included in the interim clinical considerations
- Interchangeability: COVID-19 vaccines are not interchangeable. The same mRNA vaccine product should be used for all doses of the primary series.

# Potential Vaccine Administration Errors

- More opportunities for errors with:
  - More products
  - Products not labeled for the indicated age group
  - New pediatric providers that may be unfamiliar with COVID-19 vaccines
- Most likely errors with this context:
  - Incorrect product and/or dose volume, resulting in a higher-than-authorized dose
  - Incorrect product and/or dose volume, resulting in a lower-than-authorized dose
  - Correct dose from an incorrect product
  - Vaccine administered past beyond-use date

# Resources for Preventing Vaccine Administration Errors

- Web-on-demand “mini” webinar:  
<https://www2.cdc.gov/vaccines/ed/covid19/videos/va/va.asp>
- Vaccine Administration: Preventing Vaccine Administration Errors  
<https://www.cdc.gov/vaccines/hcp/admin/downloads/vaccine-administration-preventing-errors.pdf>
- Vaccine storage, handling, preparation, and administration materials:  
<https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/index.html>

## YOU CALL THE SHOTS

**Vaccine Administration: Preventing Vaccine Administration Errors**

A vaccine administration error is any preventable event that may cause or lead to inappropriate medication use or patient harm.<sup>1</sup> Vaccine administration errors can have many consequences, including inadequate immunological protection, possible injury to the patient, cost, inconvenience, and reduced confidence in the health care delivery system. Take preventive actions to avoid vaccine administration errors and establish an environment that values reporting and investigating errors as part of risk management and quality improvement.

Vaccine administration errors may be due to causes such as:

- Insufficient staff training
- Distraction
- Changes in recommendations
- Lack of standardized protocols
- Patient misidentification
- Using nonstandard or error-prone abbreviations
- Easily misidentified products (e.g., DTaP, DT, Tdap, Td)

If an error occurs, determine how it occurred and take the appropriate actions to put strategies in place to prevent it from happening in the future. The following table outlines common vaccine administration errors and possible preventive actions you can take to avoid errors.

Error(s)	Possible Preventive Actions
Wrong vaccine, route, site, or dosage (amount); or improperly prepared.	<ul style="list-style-type: none"> <li>Circle important information on the packaging to emphasize the difference between the vaccines.</li> <li>Include the brand name with the vaccine abbreviation whenever possible (e.g., PCV13 [Pneumovax13]) in orders, medical screens, etc.</li> <li>Separate vaccines into bins or other containers according to type and formulation. Use color-coded identification labels on vaccine storage containers.</li> <li>Store look-alike vaccines in different areas of the storage unit (e.g., pediatric and adult formulations of the same vaccine on different shelves in the unit).</li> <li>Do not list vaccines with look-alike names sequentially on computer screens, order forms, or medical records, if possible.</li> <li>Consider using “name alert” or “look-alike” stickers on packaging and areas where these vaccines are stored.</li> <li>Consider purchasing products with look-alike packaging from different manufacturers, if possible.</li> <li>Establish “Do NOT Disturb” or no-interruption areas or times when vaccines are being prepared or administered.</li> <li>Prepare vaccine for one patient at a time. Once prepared, label the syringe with vaccine name.</li> <li>Do not administer vaccines prepared by someone else.</li> <li>Triple-check work before administering a vaccine and ask another staff member to check.</li> <li>Keep reference materials on recommended sites, routes, and needle lengths for each vaccine used in your facility in the medication preparation area.</li> <li>Clearly identify diluents if the manufacturer’s label could mislead staff into believing the diluent is the vaccine itself.</li> <li>Integrate vaccine administration training into orientation and other appropriate education requirements.</li> <li>Provide education when new products are added to inventory or recommendations are updated.</li> <li>Use standing orders, if appropriate.</li> </ul>

1. National Coordinating Council for Medication Error Reporting and Prevention, <https://www.nccmerp.org/about/medication-errors>  
6/18/2021 CS 32283-A

## Vaccine Administration Errors

### Preventive Actions

- Verify patient identity before administering vaccines.
- Minimize the importance of avoiding unnecessary distractions or interruptions when staff is working.
- Administer vaccines to one patient at a time. If more than one patient needs vaccines during a clinical encounter (e.g., parent with two children), assign different providers to each child. Alternatively, bring only one patient’s vaccines into the treatment area at a time, note the vaccine and patient name.
- Use standardized abbreviations to document vaccine administration (e.g., use intranasal route instead of the intranasal route—not IN, which is easily confused with IM).
- Use standardized abbreviations.
- Minimize the variance of look-alike names or generic abbreviations on computer screens, if possible.
- Provide storage and handling training based on manufacturer guidance and/or facility policy.
- Place vaccines with the earliest expiration dates in the front of the storage unit. Use the “first in, first out” principle.
- Store vaccines/diluents from storage units and areas where viable vaccines are stored.
- Monitor and report exposure to improper temperatures and contact the state or local immunization program if the vaccine manufacturer.
- Verify patient identity, if appropriate.
- Verify that you have obtained a complete vaccination history using the immunization information system, medical records, and personal vaccination records.
- Provide vaccine administration training, including timing and spacing of vaccines, into orientation and ongoing education requirements.
- For special populations, such as infants, schedule immunization visits after the birthdate.
- Verify that immunization schedules for children and adults that staff can quickly reference in clinical settings may be prescribed and administered.
- Verify that you have the correct timing and spacing in your medication preparation area. CDC has vaccine information sheets for DTaP, Tdap, Hib, PCV13, and polio vaccines to assist health care personnel in catch-up schedule for children.
- Verify that you have the correct timing and spacing in your medication preparation area. CDC has vaccine information sheets for DTaP, Tdap, Hib, PCV13, and polio vaccines to assist health care personnel in catch-up schedule for children.
- Verify that you have the correct timing and spacing in your medication preparation area. CDC has vaccine information sheets for DTaP, Tdap, Hib, PCV13, and polio vaccines to assist health care personnel in catch-up schedule for children.
- Verify that you have the correct timing and spacing in your medication preparation area. CDC has vaccine information sheets for DTaP, Tdap, Hib, PCV13, and polio vaccines to assist health care personnel in catch-up schedule for children.

11-2. Medication Errors, 2nd ed. by Cohen, Michael. Washington D.C. American Pharmacists Association, 2007.  
6/18/2021 CS 32283-A

VAERS website at <https://vaers.hhs.gov/reportevent.html>

\* At this time, COVID-19 vaccination has additional VAERS reporting requirements, including required reporting of vaccine administration errors. Please see <https://vaers.hhs.gov/faq.html> for more information.



# Resources



# Interim Clinical Considerations

- Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States:


<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html>

- FAQs for the Interim Clinical Considerations:

<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/faq.html>

- At-A-Glance COVID-19 Vaccination Schedule:

<https://www.cdc.gov/vaccines/covid-19/downloads/COVID-19-vacc-schedule-at-a-glance-508.pdf>



# Clinical Resources

- US COVID-19 Vaccine Product Information:  
<https://www.cdc.gov/vaccines/covid-19/info-by-product/index.html>

The screenshot displays the CDC's 'Vaccines & Immunizations' website. The header is dark green with the text 'Vaccines & Immunizations' in white. Below the header, a breadcrumb trail reads 'CDC > COVID-19 Vaccination'. On the right side of the header, there are social media icons for Facebook, Twitter, LinkedIn, and YouTube. The main content area is divided into two columns. The left column features a sidebar with a 'COVID-19 Vaccination' section containing a list of links: 'Product Info by U.S. Vaccine' (highlighted), 'Pfizer-BioNTech Vaccines', 'Moderna Vaccine', 'Janssen/J&J Vaccine', 'EUA', 'EUI', 'FAQs for Healthcare Professionals', 'Interim Clinical Considerations', 'Clinical Care', 'Provider Requirements and Support', and 'Training and Education'. The right column is titled 'U.S. COVID-19 Vaccine Product Information' and includes a 'Español' link. Below the title, a text box states: 'Find a suite of information and materials that are needed for each specific COVID-19 vaccine that cover administration, storage and handling, safety, and reporting.' Underneath this, there are three tabs: 'Pfizer-BioNTech', 'Moderna', and 'Janssen/J&J'. The 'Pfizer-BioNTech' tab is active, showing a section titled 'Interim COVID-19 Immunization Schedule for Ages 5+' with a calendar icon and the text: 'Find guidance for COVID-19 vaccination schedules based on age and medical condition.' The 'Moderna' and 'Janssen/J&J' tabs show a section titled 'Prevaccination Screening Form' with a checklist icon and the text: 'Download a prevaccination checklist in multiple languages.' Below this text, there is a list of language links: Arabic, Dari, English, French (Canada), Haitian Creole, Korean, Pashto, Portuguese (Portugal), Simplified Chinese, Spanish, Ukrainian, and Vietnamese, each with a small document icon.

Vaccines & Immunizations

CDC > COVID-19 Vaccination

COVID-19 Vaccination

Product Info by U.S. Vaccine

- Pfizer-BioNTech Vaccines
- Moderna Vaccine
- Janssen/J&J Vaccine
- EUA
- EUI
- FAQs for Healthcare Professionals
- Interim Clinical Considerations
- Clinical Care
- Provider Requirements and Support
- Training and Education

## U.S. COVID-19 Vaccine Product Information

[Español](#)

Find a suite of information and materials that are needed for each specific COVID-19 vaccine that cover administration, storage and handling, safety, and reporting.

Pfizer-BioNTech | Moderna | Janssen/J&J

**Interim COVID-19 Immunization Schedule for Ages 5+**  
Find guidance for COVID-19 vaccination schedules based on age and medical condition.

**Prevaccination Screening Form**  
[COVID-19 Prevaccination Guidelines](#)  
Download a prevaccination checklist in multiple languages.  
[Arabic](#), [Dari](#), [English](#), [French \(Canada\)](#), [Haitian Creole](#), [Korean](#), [Pashto](#), [Portuguese \(Portugal\)](#), [Simplified Chinese](#), [Spanish](#), [Ukrainian](#), [Vietnamese](#)



# Resources for Vaccine Recipient Education

- Recipient Education:  
<https://www.cdc.gov/vaccines/covid-19/hcp/index.html>
- COVID-19 Vaccination for Children:  
<https://www.cdc.gov/vaccines/covid-19/planning/children.html>

**COVID-19 Vaccines for Children and Teens**  
What Parents and Caregivers Need to Know

Everyone ages 5 years and older should get vaccinated against COVID-19.

If infected with COVID-19, children and teens can:

- Get really sick
- Have both short- and long-term health problems
- Spread COVID-19 to loved ones and people at school and in the community

There is no way to tell in advance how children or teens will be affected by COVID-19. Although uncommon, even healthy children can get really sick from COVID-19. Children and teens can also experience ongoing health problems after getting COVID-19 that can include physical and mental health complications that can affect their quality of life.

Getting children vaccinated can help keep them from getting really sick if they do get COVID-19. Vaccination can also help keep children in school or daycare and safely participating in group activities.

Help protect children and teens by getting them vaccinated against COVID-19.

**COVID-19 vaccines are safe for children and teens**  
The benefits of COVID-19 vaccination outweigh the known and potential risks.

COVID-19 vaccines are monitored under the most intense safety monitoring in U.S. history. Before recommending COVID-19 vaccination for children, scientists conducted clinical trials with thousands of children to make sure vaccination was safe and effective. The safety of COVID-19 vaccines continues to be monitored, including the low risk of myocarditis and pericarditis in children and teens. Serious reactions after COVID-19 vaccination are rare and are most frequently reported the day after vaccination.

Children cannot get COVID-19 from getting vaccinated and COVID-19 vaccines do not alter DNA in any way. There is also no evidence that COVID-19 vaccination causes any problems with fertility or becoming pregnant in the future.

Through ongoing safety monitoring, COVID-19 vaccination continues to be found safe for children and teens.

**Children and teens who have already had COVID-19 should still get vaccinated**

Emerging evidence indicates that people can get added protection by getting vaccinated after having been infected with the virus that causes COVID-19. So, even if a child has had COVID-19, they should still get vaccinated.


**Common side effects:**

- Fever/Headache
- Tiredness
- Cuts
- Muscle/Joint pain
- Pain at injection site
- Nausea/Dizziness

**Get started with v-safe**  
After getting your child vaccinated, enroll them in the v-safe After Vaccination Health Checker. v-safe provides personalized and confidential health check-ins after COVID-19 vaccination.

**U.S. Department of Health and Human Services**  
Centers for Disease Control and Prevention

[www.cdc.gov/covid-19/children-teens.html](https://www.cdc.gov/covid-19/children-teens.html)



For more information, contact CDC  
1-800-CDC-INFO (232-4636)  
TTY: 1-888-232-6348 [www.cdc.gov](http://www.cdc.gov)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

